Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards

Creators: Khanna, Dinesh; Furst, Daniel E; Allanore, Yannick; Bae, Sangmee; Bodukam, Vijay; Clements, Philip J; CUTOLO, MAURIZIO; Czirjak, Laszlo; Denton, Christopher P; Distler, Oliver; Walker, Ulrich A; Matucci Cerinic, Marco; Müller Ladner, Ulf; Seibold, James R; Singh, Manjit; Tyndall, Alan

Others:: Khanna, Dinesh; Furst, Daniel E; Allanore, Yannick; Bae, Sangmee; Bodukam, Vijay; Clements, Philip J; Cutolo, Maurizio; Czirjak, Laszlo; Denton, Christopher P; Distler, Oliver; Walker, Ulrich A; Matucci Cerinic, Marco; Müller Ladner, Ulf; Seibold, James R; Singh, Manjit; Tyndall, Alan

Description

SSc is clinically and aetiopathogenically heterogeneous. Consensus standards for more uniform trial design and selection of outcome measures are needed. The objective of this study was to develop evidence-based points to consider (PTCs) for future clinical trials in SSc.

Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards

Description

Additional details